India Pharma Outlook Team | Thursday, 03 September 2026
Pharma companies are betting big on critical care today as they push experimental drugs and advanced diagnostics into areas of high unmet need.
Teva reports positive mid-stage results for an immune disorder treatment that could ease life for millions with celiac disease.
Ultragenyx faces a sharp setback after its rare-disease candidate fails a late-stage trial. Meanwhile, Philips partners with Cent in India to expand preventive diagnostics and early risk detection.
These moves show how firms allocate capital and science toward conditions that still lack approved disease-modifying options or reliable early-warning tools. The outcomes highlight both the promise and the risk that define current bets in critical medical care.
Teva Pharmaceutical Industries reports that its experimental antibody TEV-408 meets the main goal of a mid-stage trial in adults with celiac disease. Celiac disease is an autoimmune condition in which gluten triggers an immune response that damages the small intestine. The condition affects more than 3 million people in the United States, according to the company.
In the study, 50 patients following a gluten-free diet received either a single subcutaneous injection of TEV-408 or a placebo. Two weeks later they consumed gluten daily for six weeks. A single injection of TEV-408 significantly reduces damage and inflammation in the small intestine compared with placebo after eight weeks. Patients also report fewer digestive symptoms, and the company identifies no new safety concerns.
Key points from the trial and outlook include:
Scotiabank analyst Louise Chen describes the dual progress in celiac disease and vitiligo as positioning the drug as an exciting contributor to Teva’s innovative medicines pipeline in areas with large unmet need.
Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future
Ultragenyx Pharmaceutical reports that its experimental drug apazunersen does not meet the main goal in a late-stage trial for Angelman syndrome. The condition affects the nervous system and impairs typical brain development in childhood. Shares of the company fall 45 percent in aftermarket trading.
In the trial the drug shows no improvement on a test of young children’s cognitive and nonverbal reasoning abilities or on an overall measure of response across multiple developmental areas. The company states that differences between treated and control groups do not support efficacy. Ultragenyx will evaluate the apazunersen program in light of this outcome and decide on its disposition.
Angelman syndrome currently has no approved disease-modifying treatment. Care focuses on controlling seizures, improving sleep, supporting communication and development, and managing movement, feeding and other medical complications. The condition occurs in about 1 in 15,000 live births and usually results from loss of function in the maternal copy of the UBE3A gene on chromosome 15.
William Blair analyst Sami Corwin notes negative implications for the company’s other study, Aurora, which tests apazunersen in patients with other genotypes. Even if that study meets its primary endpoint, commercialization could prove challenging given the limited size of the addressable population.
Last month the company received FDA approval for its gene therapy Genglycos as the first treatment for the rare metabolic disorder Von Gierke disease, underscoring the high-stakes nature of its rare-disease portfolio.
Philips announces a strategic collaboration with Cent to advance preventive diagnostics and early risk detection in India. The partnership brings together Philips’ advanced imaging innovations and Cent’s preventive health screening model. The goal is to explore new approaches to identifying health risks earlier and supporting a more proactive approach to healthcare.
As part of the collaboration, Philips deploys its helium-free, wide-bore 70 cm 1.5T MRI systems equipped with AI-enabled SmartSpeed image acceleration at Cent preventive health screening centers. The systems support enhanced screening experiences, high-quality imaging and more efficient MRI workflows. They also enable evaluation of neurological, spine and oncology-related indications and risk-assessment pathways.
The partners will evaluate MRI protocols, clinical workflows and operational requirements necessary to support preventive screening and risk assessment in asymptomatic individuals.
Globally, healthcare systems are shifting from reactive disease management toward predictive and preventive care. Advanced technologies that enable earlier risk identification have therefore become increasingly important.
The three developments illustrate the range of bets pharma and health technology companies place on critical care today. Teva’s mid-stage success in celiac disease offers a potential first approved therapy for a condition that currently depends entirely on diet.
Ultragenyx’s late-stage failure in Angelman syndrome shows how high the scientific and commercial hurdles remain in rare neurodevelopmental disorders. Philips’ collaboration with Cent underscores a parallel push into preventive imaging and early risk detection, especially in a large market such as India.
Together, these moves demonstrate that companies continue to allocate resources to areas of substantial unmet need. Successes expand treatment options and attract further investment. Setbacks refine pipelines and force harder decisions. The net result is a sector that keeps advancing critical care even when individual programs deliver mixed outcomes.
.jpg)
